Search

everythinglearnresearchcommunity

for

Search:↓

A 19-year-old male experienced significant hair loss, initially thought to be male pattern baldness (MPB), and used minoxidil and briefly finasteride. After realizing the issue was telogen effluvium (TE), he improved his diet and supplemented with vitamins, which led to substantial hair regrowth.

The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.

Dr. Bloxham's new channel will discuss verteporfin and other future hair loss treatments. Users express interest and hope for the effectiveness of these treatments.

A 25-year-old experiencing hair thinning all over the body and head, despite using minoxidil and having low vitamin D levels, is advised to seek a second opinion from a dermatologist specializing in hair loss. The likely diagnosis is diffuse alopecia areata, which may require treatment with a JAK inhibitor.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

Pyrilutamide shows promising hair growth results, but skepticism exists due to potential biases and lack of blinding in the study. Concerns about side effects and legitimacy of the product persist, with comparisons to finasteride and discussions on post-finasteride syndrome.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.

Breezula's phase 3 results are expected soon, but its release is likely delayed until 2027 or 2028. The discussion highlights the need for more hair growth stimulants like AMP-303 and PP-405, as current treatments like Dutasteride effectively stop hair loss but don't regrow hair.

A 22-year-old male experiencing diffuse thinning is using oral minoxidil and finasteride but notices his hair looks thin in sunlight. Suggestions include using hair products, considering topical minoxidil, addressing seborrheic dermatitis, and possibly trying dutasteride or a hair transplant.

A user experienced increased hair density loss after 4 months on dutasteride combined with finasteride. They are also using topical dutasteride with azelaic acid and alfatradiol but cannot tolerate antiandrogens like RU58841 due to headaches.

Scalp micropigmentation (SMP) is a debated hair loss solution, with some praising its natural look and low maintenance, while others criticize it for looking unnatural and being a temporary fix. Many prefer traditional hair restoration methods like hair transplants or medications such as finasteride and minoxidil.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

The conversation is about someone using topical dutasteride and oral minoxidil for hair loss, and they are seeking opinions on potential hair regrowth shown in a photo. Respondents agree that there is some progress.

The user is experiencing increased hair miniaturization despite using oral minoxidil, dutasteride, and microneedling. They are considering reintroducing finasteride and adjusting dutasteride dosage.

Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

The user plans to test for DHT, total testosterone, free testosterone, E2, SHBG, and prolactin while supplementing with vitamin D and monitoring ferritin levels. They are experiencing hairline thinning and are seeking advice on whether their approach is excessive or lacking.

The user experienced increased hair miniaturization and shedding despite using finasteride, topical minoxidil, microneedling, and other treatments. They are considering more aggressive treatments or a hair system if no improvement occurs by the end of 2025.

The conversation discusses a user's 3.5-month experience using pyrilutamide and minoxidil for hair loss, with some perceived improvement in the temples but potential recent regression. Another user suggests that maintaining the current hairline, even without improvement, is positive.

A 24-year-old male started using finasteride, minoxidil, biotin, and vitamin D for hair loss but noticed worsening thinning and white patches on his temples. He seeks advice on improving his regimen, which includes topical minoxidil and a shampoo for seborrheic dermatitis.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

A 20-year-old is using oral minoxidil, finasteride, and a dermastamp to address hair loss but is concerned about continued thinning and lack of visible regrowth after six months. They are questioning if diet, vitamin deficiencies, or dosage adjustments could impact progress.

The user is using oral Minoxidil, oral Dutasteride, microneedling, and RU58841 for hair loss, noticing slow progress with small hairs appearing. They are inconsistent with microneedling frequency, sometimes doing it weekly or skipping weeks.

The user is experiencing new hair growth after using oral dutasteride, topical minoxidil, and microneedling, but is concerned about black dots on the hairline, which might be clogged pores or dormant follicles. The user previously used a topical minoxidil/finasteride spray and had good results, despite a shedding phase after switching treatments.

The user experienced significant hair regrowth in 5 weeks using Minoxidil, Finasteride, Dutasteride, biotin, collagen, derma stamping, and a mixture of oils, leading others to label them a "hyper responder." Some users advised caution with microneedling frequency to avoid potential scarring.

User with diffused thinning hair prefers receding temples, as hair transplant could fix it. Finasteride and minoxidil suggested to improve hair density.

The user has been using a hair solution with 0.3% finasteride and 5% minoxidil, along with microneedling, but is experiencing more thinning on one side. Suggestions include checking application techniques and ensuring microneedling is not overdone.

The user has been taking oral minoxidil, dutasteride, and biotin for 3 months and noticed changes in hair texture, suggesting potential regrowth or stabilization. Baby hairs and increased hair density are seen as positive signs.